Join our daily newsletter At The Bell to receive exclusive market insights
In this latest episode of HotCopper’s long-form podcast From The Wire, senior markets reporter Jonathon Davidson sat down with Paradigm Biopharmaceuticals (ASX:PAR) chief executive officer (CEO) Paul Rennie.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Disclaimer: This content is disseminated in partnership with Paradigm Biopharma Ltd. It is intended to inform investors and should not be taken as financial advice.
In this podcast, we explore the mindset of business leaders and emergers, getting a look at what makes the heads of ASX-listed companies tick.
What’s got Paradigm’s Paul Rennie ticking across his recent history in the industry is osteoarthritis – a condition well-known for impacting bones and mobility, but which has psychological and emotional implications.
Paradigm Biopharmaceuticals is developing its flagship drug iPPS to treat the condition, which reflects one massive unmet need. And with unmet needs comes the potential for serious returns – along with a fairly easy-to-understand value prop.
Expect a lot of newsflow from Paradigm throughout 2026 – especially because the company’s now embarking on Phase Three trials with an international bent, with interim data to land around halfway through next year. And after that? Onto the desks of the U.S. healthcare regulator, the FDA.
Join the discussion. See what HotCopper users are saying about Paradigm Biopharma Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
